Evernorth’s $100 Million AI Plan Tightens Accredo’s Hold

Evernorth is putting $100 million through 2028 into Pharmacy Forward, an AI program at Accredo that it says will cut specialty fill times in half. The Cigna Group’s health services arm also projects about $400 million in value by the end of 2028 for more than one million Accredo patients a year.

Those tools run on a stack Evernorth already owns. Express Scripts handles prior authorization. Accredo fills the scripts. In September 2025 Evernorth also put $3.5 billion of preferred stock into Shields Health Solutions, which helps hospitals run specialty pharmacies.

Four AI Bets on a $100 Million Check

The company unveiled the program on July 1, 2026, in Bloomfield, Connecticut. It launches first at Accredo Specialty Pharmacy, which treats people with cancer, multiple sclerosis, rheumatoid arthritis, and other chronic and complex conditions through condition-specific Therapeutic Resource Centers. Evernorth says a $100 million investment through 2028 will let care teams spend more time on clinical work while shrinking processing timelines.

Patients navigating complex health conditions need comprehensive, expert support, often during some of the most difficult moments in their lives.

Matt Perlberg, President of Evernorth pharmacy and care delivery, Evernorth newsroom

Perlberg also sits as executive vice president of customer innovation for The Cigna Group. On NYSE Live the same day, he walked through the cash, the patient count, and the shipping radius.

Pharmacy Forward applies AI across four named areas: clinical care, prescription intake, administration, and medication fulfillment. The targets below are Evernorth’s, not audited results.

PHARMACY FORWARD TARGETS

Katya Andresen, chief data, digital and AI officer at The Cigna Group, said AI lets the company “fundamentally reimagine how we support each patient’s journey” by combining real-time data, analytics, and clinical staff. Evernorth says it will later extend many of the same tools to its other pharmacies, which include Express Scripts Pharmacy.

Evernorth Already Owns the Prior Auth Gate

Rx Readiness is the piece that sounds like a patient win, and for someone waiting on a cancer or transplant drug it can be. It is also a speed-up of a bottleneck inside the same corporate family. Express Scripts is the pharmacy benefit manager. Accredo is the specialty pharmacy. Prior authorization is the paperwork wall between a doctor’s order and a filled specialty drug, and both sides of that wall sit under Evernorth.

Perlberg’s portfolio already includes Accredo, CuraScript SD, Express Scripts Pharmacy, and MDLIVE. Evernorth itself houses Express Scripts, Accredo, eviCore, and MDLIVE, employs more than 40,000 people, and says it serves 190 million people. That is not a startup bolting AI onto a stand-alone mail pharmacy. It is the health-services arm of a national insurer teaching its own specialty channel to move faster.

CVS Caremark and OptumRx already run affiliated specialty pharmacies of their own. An Accredo speed-up is a fight for the same high-cost channel, not a side experiment in chatbots. Specialty drugs are the expensive, often refrigerated therapies that independent shops struggle to stock, ship, and get paid for. Whoever times the outreach, completes the prior auth, and parks the box one day from the door keeps the patient.

THE SPECIALTY STACK, 2024 TO 2026

1. July 9, 2024: FTC staff publish an interim report on pharmacy benefit managers and affiliated pharmacies.
2. January 14, 2025: FTC staff publish a second interim report on specialty generic markups at those pharmacies.
3. September 2, 2025: Evernorth announces $3.5 billion of preferred stock in Shields Health Solutions.
4. October 29, 2025: Evernorth opens a 200,000-square-foot specialty care site in Newark, Delaware.
5. January 6, 2026: Nine patients sue Accredo, Express Scripts, Evernorth, and The Cigna Group in Chicago federal court.
6. July 1, 2026: Evernorth launches Pharmacy Forward at Accredo with $100 million through 2028.

The sequence is the point of the spend. AI arrives after the regulator reports, after the hospital-channel check, after the new warehouse, and after the delay suit.

68% of Specialty Drug Revenue, and Rising

Federal Trade Commission staff, in a July 2024 interim report, found that the three largest PBMs processed nearly 80 percent of U.S. prescriptions among about 6.6 billion dispensed in 2023. Caremark, Express Scripts, and OptumRx are the three. The top six PBMs processed more than 90 percent.

A January 14, 2025, follow-up found that pharmacies tied to those three firms took 68% of specialty-drug dispensing revenue in 2023, up from 54% in 2016, a 14-point gain over seven years. Staff said the same firms marked up many specialty generics at affiliated pharmacies by hundreds or thousands of percent, including drugs used for cancer, HIV, multiple sclerosis, and pulmonary hypertension.

FTC STAFF FIGURES ON SPECIALTY GENERICS

• Excess take: Affiliated pharmacies generated more than $7.3 billion in excess revenue above estimated acquisition cost from 2017 through 2022.
• Growth rate: That excess rose at a 42% compound annual rate from 2017 through 2021.
• Concentration: The top 10 specialty generics produced $6.2 billion of that excess, 85% of the total.
• Spread pricing: The three PBMs separately generated an estimated $1.4 billion by billing plan sponsors more than they paid pharmacies on the same drugs.

Then-FTC Chair Lina M. Khan said the second report found that the three major PBMs “hiked costs for a wide range of lifesaving drugs, including medications to treat heart disease and cancer.” Staff also wrote that 12% of the aggregated operating income of the parent companies’ PBM and pharmacy segments in 2021 came from dispensing the studied specialty generics. In that year plan sponsors paid $4.8 billion for those drugs and patients paid $297 million in cost sharing.

Drug Channels Institute estimated that retail, mail, long-term care, and specialty pharmacies dispensed $293.4 billion in specialty drugs in 2025, up 9.6% from 2024. The three largest specialty pharmacies, all PBM-owned, took two-thirds of that prescription revenue. Specialty dispensing accounted for more than one-third of PBMs’ total gross profits in 2025, the institute said. Independents still run the largest share of accredited locations, and they keep a thicker slice of manufacturer exclusive networks. PBM-affiliated pharmacies reach only 20% of specialty products that use exclusive dispensing. Revenue is the other map.

What the January Lawsuit Says About Delays

On January 6, 2026, nine patients filed a federal class action in the U.S. District Court for the Northern District of Illinois. The case, Wolf et al. v. Accredo Health Group, Inc. et al., No. 1:26-cv-00098, names Accredo, Express Scripts, Evernorth, and The Cigna Group. The complaint alleges that Express Scripts ties PBM services to Accredo, shuts out rival specialty pharmacies, and leaves captive patients with delayed fills. Those are allegations. A court has not ruled on them.

Trapping patients within this incestuous system of nested companies violates state and federal antitrust laws and is unfair and dangerous.

Michael Kanovitz, attorney, Loevy + Loevy press release

The plaintiffs’ lawyers describe delays that look like the exact queue Pharmacy Forward now says AI will shorten.

WHAT THE PLAINTIFFS DESCRIBE

• Heather Lisser: A Wisconsin transplant recipient, she says she has spent hours on the phone after refill authorizations failed, bouncing between scripts, and has driven more than an hour for an emergency bridge fill to protect a transplanted organ.
• Jennifer Bellucci: A Texas parent of three minor children with juvenile idiopathic arthritis, insured through TRICARE West, she says she has waited weeks, found a prescription canceled without warning, and once driven seven hours to Houston for a free hospital sample.
• The ask: The suit seeks an injunction, a class of Accredo customers, and damages under the Sherman Act and state law.

Attorney Aaron Tucek said the firm had heard from hundreds of people with matching stories and called the pattern “the foreseeable result of a business plan that puts profit over meeting patients’ needs.” Pharmacy Forward does not mention the case. It does promise to complete prior auths more cleanly, find copay help sooner, and call patients in the window they actually pick up the phone. If those tools work, some of the phone-tree horror in the complaint gets cheaper to prevent. If they mainly route more volume through the same exclusive channel, the suit’s tying claim and the AI program can run in parallel for years.

A Same-Day Radius From Nearly 40 Sites

One Fulfillment Network is the least chatty part of the announcement and the hardest for a rival shop to copy. Accredo is expanding capacity, staff, and skills at many of its nearly 40 care facilities so more drugs leave by ground from a site close to the patient. Air and long ground hauls fail more often in weather. AI, Evernorth says, will keep scoring location, timing, and handling rules to pick the send site.

The physical build-out started before the AI brand name. On October 29, 2025, Evernorth opened a 200,000-square-foot specialty care facility in Newark, Delaware, with Perlberg calling it the company’s largest and most advanced U.S. specialty site. Accredo is expected to dispense 1.5 million specialty prescriptions a year from that building. CuraScript SD, the sister distributor on the same campus, is expected to ship 200,000 orders a year to more than 12,000 health-care providers. More than 100 people work there.

THE ACCREDO FOOTPRINT BEHIND THE SOFTWARE

• Patients and scripts: Accredo serves about one million patients a year and dispenses nearly 8 million prescriptions for complex conditions.
• Clinical bench: Fifteen Therapeutic Resource Centers, more than 800 specialty pharmacists, and about 600 field nurses who can infuse drugs at home in all 50 states.
• Money already moving: Accredo says it secured $2.7 billion in copay assistance for specialty patients in 2025, the same assistance category Rx Readiness now says AI will flag earlier.
• Ship target: 90% of patients inside a same-day or one-day ground radius once the nearly 40 sites are built out.

A local independent specialty pharmacy can hire a nurse and buy a fridge. It cannot stand up nearly 40 send sites, a 200,000-square-foot hub, and a routing model that already knows which Accredo patient is due a cold box tomorrow. Hospital systems are trying a different path. Accredited hospital and health-system specialty pharmacies grew from 106 locations in 2017 to 553 in 2025 and now make up 28% of accredited specialty sites, per Drug Channels Institute. That is the channel Shields was built to serve.

Shields Health Solutions Gets a $3.5 Billion Check

On September 2, 2025, Evernorth announced a $3.5 billion investment in Shields as preferred stock. The check landed as Sycamore Partners split Shields out of Walgreens Boots Alliance into a stand-alone company. Shields partners with more than 80 health systems, more than 1,000 hospitals and clinics, in nearly all 50 states, helping those systems run in-house specialty pharmacies.

David M. Cordani, chairman and chief executive of The Cigna Group, said demand for specialty drugs is growing fast and that Evernorth is “uniquely positioned to serve the rapidly expanding number of individuals living with complex and chronic conditions and the doctors who care for them.” The preferred stock, the company said, was not expected to dent 2025 adjusted earnings guidance.

$3.5 billion is 35 times the $100 million AI budget. Pharmacy Forward is the home-delivery and call-center rewrite. Shields is the hospital-side option, so Evernorth has a paper claim on specialty fills whether the patient is steered to Accredo’s shipper or to a health-system pharmacy that Shields helps operate. Evernorth also owns CarepathRx, another firm that helps hospitals with specialty pharmacy operations, according to Drug Channels Institute’s 2026 mapping of the channel.

Hospital pharmacies make money in part through 340B discounts. PBM-owned mail pharmacies make money in part by keeping the fill. Putting preferred equity into the hospital helper while pouring AI into Accredo is how one parent company shows up on both doors. Patients may still get a faster box. Rivals get a narrower hallway.

Where $400 Million in Value Is Supposed to Land

Evernorth expects Pharmacy Forward to generate about $400 million in value by the end of 2028. That figure is four times the $100 million cash commitment. The company has not said whether the $400 million is avoided hospital bills, extra dispensing margin, labor saved on paperwork, copay dollars captured, or some mix. It also has not said how much of that value accrues to patients, plan sponsors, or The Cigna Group.

WHAT WE KNOW

• The cash: $100 million through 2028, first at Accredo, with a later pass to other Evernorth pharmacies.
• The targets: Fill time cut in half after Accredo receives a prescription, paperwork time down up to 50%, digital pathway use up 25%, 90% of patients inside a same-day or one-day ground radius.
• The rest of the stack: $3.5 billion of preferred stock in Shields, a 200,000-square-foot Newark hub, and a live antitrust case filed January 6, 2026.

WHAT IS UNCONFIRMED

• The $400 million: No public formula, no third-party audit, no split between patient savings and company earnings.
• The half-time fill: A projection, not a measured 2026 result.
• The lawsuit: Allegations only. No finding that Accredo illegally tied or delayed care.

Adherence above 80% would be a clinical result worth having, and a 50% cut in clinician paperwork would be a labor result clinicians would feel. The shipping radius is a logistics result a patient can date-stamp. All three can be true at once, and the parent can still be the party that books the $400 million. Independent specialty pharmacies, already a minority of specialty revenue, cannot match a nearly-40-site ground net or a PBM that completes its own prior auths. Hospital systems can, which is why the Shields check is larger than the AI budget.

Evernorth says it will spread pieces of Pharmacy Forward to its other pharmacies as the program matures. The clock on the $100 million and the $400 million claim both run to the end of 2028. The Wolf docket runs on its own calendar in Chicago.

Disclaimer: This article is news reporting and analysis of a company program, court filings, and regulator staff reports. It is informational only and is not medical advice, pharmacy advice, or investment advice, and it is not a prediction of how Pharmacy Forward, Accredo fills, or The Cigna Group’s shares will perform. Readers making treatment or medication decisions should consult a licensed physician or pharmacist who knows their case, and readers making financial decisions should consult a qualified investment professional. Figures, case status, and program targets reflect the cited company, court, and FTC materials as of the dates on those documents and can change as the 2028 program, the Illinois suit, and the FTC inquiry move.